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Edited by Horst FeldmannAbstract Tumours are immunogenic and are commonly inﬁl-
trated by anti-cancer eﬀector cells. Why, then, are they not
completely rejected by the host? Unfortunately, tumours are
Darwinian paragons, winning the battle against the forces of
natural immune selection. Some of the latter can even act as
double-edged swords, actually being subverted to become pro-
tumorigenic. Prevention or reversal of tumour escape from the
immune response therefore oﬀers the possibility of reconstituting
eﬀective anti-tumour immunity and remains the major challenge
for 21st century tumour immunology.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tumours are immunogenic. They possess antigens either not
expressed or expressed at low levels by normal tissues. These
are recognizable by the immune system. The former include
products of chromosomal translocations or mutations, the
latter transcription factors, surface receptors or foetal anti-
gens. Moreover, tumours are commonly inﬁltrated by tumour
antigen-speciﬁc T cells. Why, then, are they not completely
rejected by the host? The explanation currently favoured is
that tumours are Darwinian paragons commonly winning the
battle against the forces of natural immune selection. There is
also a growing appreciation that many responses deﬁned as
anti-tumour eﬀector mechanisms can act as double-edged
swords, becoming not only ineﬀective but even pro-tumori-
genic depending on the evolving tumour–host relationship.
Examples of such potentially double-edged swords are inter-
leukin (IL) 2 (pro-apoptotic for activated T cells), interferon
(IFN)-c (induces ligands for T and natural killer (NK) cell
inhibitory receptors), angiogenesis inhibition (causes hypoxia-
mediated induction of growth factors promoting metastasis),* Fax: +49-7071-294467.
E-mail address: graham.pawelec@uni-tuebingen.de (G. Pawelec).
Abbreviations: IFN, Interferon; IL, interleukin; NK, natural killer;
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cells), etc. Immune selection pressure itself, resulting in out-
growth of resistant tumour variants, could also be viewed in
this light. On the other hand, knowledge of the many tumour
escape pathways oﬀers the theoretical possibility of reconsti-
tuting anti-tumour immunity [1]. For many years now, clinical
vaccination trials have sought to trigger or enhance anti-tu-
mour immunity, but thus far, on careful analysis, with rather
disappointing results. Many explanations could account for
the unimpressive success rates, from the classical concept of
immunoselective pressure giving rise to resistant variants (now
often termed ‘‘immunoediting’’), to the more recent realization
that tumour-induced alterations to the patient’s immune sys-
tem may subvert anti-cancer responses and even encourage
tumour growth. These escape mechanisms may be classiﬁed
into at least the following major groups: alteration of MHC
class I and tumour antigen expression by tumour cells [2];
dysregulated expression of adhesion/accessory molecules by
tumour and/or antigen presenting cells [3]; tumour utilization
of products of stimulated leukocytes, i.e., immunostimulation
of cancer [4]; secretion of immunosuppressive soluble factors
either by tumour cells or inﬁltrating T cells or both [5]; and, as
treated below, induction of immune non-responsiveness via
anergy induction or clonal deletion of responding T cells, or
induction of suppressor cells; and changes in T cell signal
transduction molecules.
Tumour escape from immunosurveillance represents the last
series of hurdles to be overcome in formulating truly eﬀective
cancer immunotherapy [1], but given the immense plasticity of
the tumour cell, and the complex balance between pro- and
anti-tumour activity of the very same eﬀector pathways, this
remains a major challenge for the 21st century. I have recently
reviewed progress in our understanding of tumour escape
mechanisms [6] and therefore in the present article I focus
on alterations to T cell immunity in cancer patients and how
these might be manipulated to rejuvenate anti-cancer eﬀector
mechanisms.2. Induction of T cell unresponsiveness
2.1. T cell destruction
Clearly, were the tumour able to simply destroy any anti-
cancer T cells, this would be the most direct and eﬀective
protective mechanism. There is some evidence that this may
occur via the classical pathway of central tolerance inductionblished by Elsevier B.V. All rights reserved.
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not those already present before tumour formation. Perhaps
more importantly, peripheral tolerance induction may be
mediated by tumour-induced T cell death. One major mecha-
nism therefore fas/fas-ligand interactions, still remains con-
troversial. Shortly after activation, T cells begin to express fas
(CD95). These CD95+ T cells may become susceptible to fas
ligand-mediated cell death, although other outcomes are also
possible (in fact, in the context of tumour escape, the non-
apoptotic consequences of fas signalling have been relatively
neglected (for review, see [8]). Following the ﬁrst report several
years ago, many types of tumour have been reported to express
fas-ligand (for review see [9]). Therefore, either as a conse-
quence of the interaction of fas-ligand on the tumour with
CD95 on the T cells, or as a consequence of ‘‘fratricide’’ (i.e.,
fas/fas-ligand interactions between T cells [10]), anti-tumour T
cells are killed. Fas-ligand expression by tumour cells may also
negatively aﬀect non-T cell components of anti-cancer immu-
nity [11]. These important facets of tumour–host interaction
continue to be discussed in a lively manner, but a consensus is
clearly emerging that fas/fas-ligand interactions are indeed
important for tumour escape [9,12–14]. Protecting T cells
against this fas-mediated apoptosis may therefore enhance
anti-tumour immunity. This might be achieved by selectively
interfering with T cell apoptosis pathways or blocking fas-
ligand expression.
2.2. T cell anergy
The tumour environment may be unconducive to T cell
function even if the cells themselves are not killed. Mechanisms
including antigen-speciﬁc anergy-induction may be important
in early tumour progression [15], whereas non-speciﬁc immu-
nosuppression by a variety of mechanisms may be more im-
portant later. Anergy induction may occur when T cells receive
activatory signals in the absence of costimulation or in the
presence of over-riding negative signalling (see Table 1). TheTable 1
T cell costimulation
Receptor Ligand Main eﬀect
CD28 family – expressed on T cells only
CD28 CD80, 86 Strong costimulation
CD152 CD80, 86 Dominant coinhibition
ICOS B7RP-1 Accessory costimulation
PD-1 PD-L1, L2 Weak coinhibition when IL
2 limiting (blocks ICOS,
not CD28)
Unidentiﬁed B7-H3 Accessory costimulation
(" IFN-c) (but coinhibition
also reported)
BTLA B7x Similar to PD-1
TNFR family – expressed mostly on T cells
CD40 CD154 DC activation
CD137 4-1BBL Accessory costimulation
CD134 OX-40L Accessory costimulation
KIR family – expressed on NK cells, subpopulations of T cells
KIR2DL, 3DL MHC class I Inhibition
KIR2DS MHC class I Stimulation
Lectin-like receptor family – expressed on NK cells, subpopulations of T
cells
NKG2A HLA-E Inhibition
NKG2D HLA-E Stimulation
KLRG-1 Unidentiﬁed Dominant inhibitionformer can occur when the costimulatory receptor CD28 on
T cells is either absent or not ligated, the latter when negative
receptors such as CD152 or NKG2A are present and ligated
on T cells. Additionally, alterations to the ‘‘quality’’ of the
TCR-mediated signal due to the nature of the antigen recog-
nized may contribute to anergy induction. For example, nat-
urally occurring peptide sequences from endogenous as well as
foreign proteins can act as partial agonists for the melanoma
antigen MART1/Melan A (peptide positions 27–35) and an-
ergize anti-tumour T cells [16]. Moreover, the presence of such
anergy-inducing peptides on the melanoma cell surface can
prevent T cell activation by immunodominant peptides [17]).
Awareness of these possibilities is essential for designing
appropriate tumour vaccine, to avoid potentially dangerous
anergy induction by vaccination with immunogenic peptides
representing tumour antigens [18]. Eﬀector T cells identiﬁed in
melanoma patients may already be anergic and unable to lyse
target cells or secrete cytokines on activation [19]. Thus, not
only must vaccination seek to avoid de novo anergy induction
but also reverse the anergy which may already be present in the
patient. This may be achieved by increasing the stimulatory
environment using cytokines or transfected costimulatory
molecules, as well as antibodies (as recently shown, for ex-
ample, using agonistic CD137 antibody to break anergy in an
animal tumour model [20]).
2.3. Suppressor T cells
Anergic T cells may act as suppressor cells [21]; addition-
ally, there may be separate lineages of regulatory cells. The
recent renaissance of interest in suppressor cells has lead to
the re-interpretation of many older data, which had previ-
ously been dismissed as artefacts (for review, see [22]). The
realization that CD4+ CD25+ regulatory cells play an im-
portant role in many aspects of immunological tolerance has
led to attention being focused on such cells also in cancer (for
review, see [23]). This allows for the development of potential
new treatment modalities, for example, in animal models,
injection of CD25 mAb preferentially depletes CD25+ CD4
cells and can prevent tumour progression; removing ‘‘natu-
rally’’ activated (i.e., CD25+) CD4+ cells has the same eﬀect
[23,24].
2.4. T cell activation blockade
Even if not killed, anergized or suppressed, T cells inﬁl-
trating the tumour may be rendered ineﬀective by modulation
of their activatory signal transduction ability. In fact, these
alterations may themselves be partially responsible for the
observed outcome of cell death, anergy induction or suscep-
tibility to suppression. Both the T cell receptor for antigen
itself (TCR) and positive and negative costimulatory receptors,
as alluded to above, may be involved in this inhibitory process.
2.4.1. TCR. The original observation that T cell signal
transduction is compromised in tumour-bearers [25] has sub-
sequently been conﬁrmed and extended to a variety of human
tumours, including renal, colorectal, ovarian, liver, gastric,
oral, prostate, pancreatic and cervical carcinomas, glioblasto-
mas and melanomas (for review, see [26]). Of particular in-
terest is the repeatedly documented correlation between these
alterations and disease stage in many diﬀerent cancers. Loss of
TCR CD3f chain, or abnormal association between zeta
chains and other CD3 components, might help to explain the
observed gradual decline of cell-mediated responses in patients
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possibilities for reversal of this CD3f loss are being tested. In
chronic myelogenous leukaemia, for example, the majority of
patient’s T cells were found to be CD3f deﬁcient, and this
could be at least partially reversed by stimulation with CD3
mAb, IL 2 and IFN-a in vitro [27]. Whether the same sort of
manipulation would be eﬀective in vivo is not yet clear.
However, several studies are beginning to suggest that this
might be so: normalised CD3f expression in patients with
myeloid malignancies after successful remission induction has
been reported [28] and a majority of renal cancer patients
treated with IL 2, IFN-a and lymphokine-activated killer cells
also showed improvement of low f chain expression [29].
Speciﬁc active immunotherapy itself may stimulate the im-
mune system suﬃciently to allow reconstitution of CD3f chain
expression [30] perhaps due to local production of IL 2 which
can reverse CD3f suppression, at least in vitro [26]. While
many mechanisms may account for CD3f downregulation, it is
encouraging that it may be potentially reversible by relatively
simple manipulations.
2.4.2. Costimulation and coinhibition. A complex constel-
lation of monomorphic positive and negative costimulatory
receptors, including CD28, CD152, respectively, and many
others of this type [31] modulate the signals received via the
highly polymorphic antigen-speciﬁc TCR (Table 1). Hence,
even though the TCR may be fully functional, or be recon-
stituted as described in the preceding section, T cell inhibition
might still occur as a consequence of upregulated negative and/
or downregulated positive costimulatory receptors. The pan-
oply of diﬀerent receptors, of which the list in Table 1 is cer-
tainly by no means complete, renders prediction of the
outcome of each T cell stimulation extremely complicated and
cries out for systems-biological mathematical modelling.3. Unifying hypothesis: cause of T cell dysfunction is chronic
antigenic stress
Be that as it may, it is clear that in chronic infection or in-
ﬂammatory disease, clonal expansions of dysfunctional
T cells are found and can be identiﬁed by their expression of
these positive and negative coreceptors, and other surface
molecules [32]. These cells may accumulate because the source
of antigen stimulating them cannot be cleared. In the elderly,
persistent herpes viruses, especially CMV, provide a reservoir
of antigen and a constant stimulus to T cell-mediated immu-
nity, and T cells of the same type can be identiﬁed. In cancer
patients, chronic exposure to tumour antigens may result in a
similar phenomenon. These conditions are characterized by
the accumulation of apoptosis-resistant anergic CD8 cells at
the expense of decreased numbers of CD4 helper cells. In the
very elderly, accumulation of CMV-speciﬁc CD8 cells, de-
creased numbers of CD4 cells and an inverted CD4:8 ratio
predict incipient mortality [33]. We suggest that a similar sit-
uation applies to cancer: chronic antigenic stress results in an
accumulation of dysfunctional CD8 cells, selective clonal de-
letion of CD4 cells and consequently decreased immune re-
sponses to the target as well as to other antigens. We further
hypothesize that dysfunctional CD8 cells accumulate because
of selective loss of the CD4 helper cells, which, at least in vitro,
become more susceptible to lysis on chronic stimulation [34] incontrast to CD8 cells, which become more resistant [35]. We
therefore suggest that replacing the lost CD4 cells will ‘‘reju-
venate’’ the response. This could be approached by generating
such CD4 cells in vitro and infusing them into the patient as
adoptive immunotherapy or intervening in vivo to achieve this
aim by targeting the involuting thymus to stimulate increased
production of larger numbers of new T cells. The former aim
may be the more amenable at present. Approaches to extend
the lifespan of CD4 cells may include genetic manipulations to
protect against damage, for example, enforced expression of
heat shock proteins (because there is an age-associated de-
crease in expression of various stress response proteins with
age in humans [36]) or proteasome ß1 or ß5 chains (because
age-associated impaired proteasome function is associated
with decreased stress resistance which can be reversed by gene
transfection [37]). They may also target enhancing repair of
damage nonetheless accumulating, as for example, is now
possible in yeast [38]. Expression of the catalytic component of
telomerase, hTERT, is also a candidate, although the mecha-
nisms of its action, and the still unresolved issue of why
hTERT sometimes but not always results in ‘‘immortaliza-
tion’’ [39,40] (at least of human CD8 clones), requires further
investigation. Blockade of negative receptors such as KLRG-1
and CD152 may also be beneﬁcial, but given that the com-
plexity and probable redundancy of signalling systems (Table
1) may be diﬃcult to achieve. Nonetheless, in the T cell clonal
model of immunosenescence [41] it is the level of expression of
the major costimulatory receptor CD28 which seems dominant
[42]. Therefore, controlling the level of functional CD28 ex-
pression may be paramount. This could be achieved by ma-
nipulating the cytokine microenvironment to prevent TNF-a
from downregulating CD28 [43], for example, using neutral-
izing antibodies [42] and/or by the ability of IL 12 to upre-
gulate CD28 expression [44]. Gene transfer to enforce ectopic
expression of CD28 may also be a suitable avenue to pursue
[45].
Immune escape mechanisms that are being identiﬁed in tu-
mour immunology may be informative for microbiological
escape [3]. So the means to rectify this state of aﬀairs, which
are beginning to become available, may be of enormous clin-
ical importance not ‘‘only’’ for cancer but for a diversity of
other intractable diseases as well.Acknowledgements: The author’s experimental work was supported by
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